



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2020 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer: 922 215 871
Organisasjonsform: Norskreg. utenlandsk foretak
Foretaksnavn: JAZZ PHARMACEUTICALS DENMARK APS
Forretningsadresse: Gammel Kongevej 1
DK-1610 COPENHAGEN

Regnskapsår

Årsregnskapets periode: 01.01.2020 - 31.12.2020

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Ja
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Samantha Pearce
Dato for fastsettelse av årsregnskapet: 28.05.2021

Grunnlag for avgivelse

År 2020: Årsregnskapet er elektronisk innlevert
År 2019: Tall er hentet fra elektronisk innlevert årsregnskap fra 2020

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 03.08.2022



Resultatregnskap

Beløp i: DKK	Note	2020	2019
RESULTATREGNSKAP			
Inntekter			
Bruttofortjeneste		16 469 482	7 280 478
Sum inntekter		16 469 482	7 280 478
Kostnader			
Lønnskostnad	1	14 301 578	7 655 373
Sum kostnader		14 301 578	7 655 373
Driftsresultat		2 167 904	-374 895
Annen finanskostnad	2	333 292	258 084
Sum finanskostnader		333 292	258 084
Netto finans		-333 292	-258 084
Ordinært resultat før skattekostnad		1 834 612	-632 979
Skattekostnad på ordinært resultat	3	294 107	-138 296
Ordinært resultat etter skattekostnad		1 540 505	-494 683
Årsresultat		1 540 505	-494 683
Overføringer og disponeringer			
Overføringer til/fra annen egenkapital		1 540 505	-483 683
Sum overføringer og disponeringer		1 540 505	-483 683



Balanse

Beløp i: DKK	Note	2020	2019
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Utsatt skattefordel		330 757	195 980
Sum immaterielle eiendeler		330 757	195 980
Sum anleggsmidler		330 757	195 980
Omløpsmidler			
Varer			
Varer		7 129 245	
Sum varer		7 129 245	
Fordringer			
Kundefordringer		7 687 706	
Andre fordringer		1 693 843	148 880
Selskpasskatt		591 647	65 316
Konsernfordringer			6 591 390
Sum fordringer		9 973 196	6 805 586
Bankinnskudd, kontanter og lignende			
Bankinnskudd, kontanter og lignende		1 852 821	2 501 854
Sum bankinnskudd, kontanter og lignende		1 852 821	2 501 854
Sum omløpsmidler		18 955 262	9 307 440
SUM EIENDELER		19 286 019	9 503 420
BALANSE - EGENKAPITAL OG GJELD			
Egenkapital			
Innskutt egenkapital			
Selskapskapital		50 000	50 000
Sum innskutt egenkapital		50 000	50 000



Balanse

Beløp i: DKK	Note	2020	2019
Opptjent egenkapital			
Annen egenkapital		7 578 522	6 038 017
Sum opptjent egenkapital		7 578 522	6 038 017
Sum egenkapital		7 628 522	6 088 017
Sum langsiktig gjeld		0	0
Kortsiktig gjeld			
Leverandørgjeld		2 042 121	876 879
Kortsiktig konserngjeld		4 137 586	
Annen kortsiktig gjeld		5 477 790	2 538 524
Sum kortsiktig gjeld		11 657 497	3 415 403
Sum gjeld		11 657 497	3 415 403
SUM EGENKAPITAL OG GJELD		19 286 019	9 503 420



Brønnøysundregistrene

ÅRSREGNSKAP FOR REGNSKAPSÅRET 2020 - GENERELL INFORMASJON

Journalnummer: 2021 856460

Enheten

Organisasjonsnummer: 922 215 871
Organisasjonsform: Norskreg. utenlandsk foretak
Foretaksnavn: JAZZ PHARMACEUTICALS DENMARK APS
Forretningsadresse: c/o Jazz Pharmaceutical Denmark Asp
Gammel Kongevej 1
DK-1610 KØBENHAVN

Regnskapsår

Årsregnskapets periode: 01.01.2020 - 31.12.2020

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Ja
Benyttet ved utarbeidelsen av
årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Samantha Pearce
Dato for fastsettelse av årsregnskapet: 28.05.2021

Grunnlag for avgivelse

År 2020: Årsregnskap er elektronisk innlevert.
År 2019: Tall er hentet fra elektronisk innlevert årsregnskap fra 2020.

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 26.10.2021



Organisasjonsnr: 922 215 871
JAZZ PHARMACEUTICALS DENMARK APS

RESULTATREGNSKAP

Beløp i: DKK	Note	2020	2019
RESULTATREGNSKAP			
Inntekter			
Bruttofortjeneste		16 469 482	7 280 478
Sum inntekter		16 469 482	7 280 478
Kostnader			
Lønnskostnad	1	14 301 578	7 655 373
Sum kostnader		14 301 578	7 655 373
Driftsresultat		2 167 904	-374 895
Annen finanskostnad	2	333 292	258 084
Sum finanskostnader		333 292	258 084
Netto finans		-333 292	-258 084
Ordinært resultat før skattekostnad		1 834 612	-632 979
Skattekostnad på ordinært resultat	3	294 107	-138 296
Ordinært resultat etter skattekostnad		1 540 505	-494 683
Årsresultat		1 540 505	-494 683
Overføringer og disponeringer			
Overføringer til/fra annen egenkapital		1 540 505	-483 683
Sum overføringer og disponeringer		1 540 505	-483 683



Organisasjonsnr: 922 215 871
JAZZ PHARMACEUTICALS DENMARK APS

BALANSE

Beløp i: DKK **Note** **2020** **2019**

BALANSE - EIENDELER

Anleggsmidler

Immaterielle eiendeler

Utsatt skattefordel 330 757 195 980
Sum immaterielle eiendeler 330 757 195 980

Sum anleggsmidler 330 757 195 980

Omløpsmidler

Varer

Varer 7 129 245
Sum varer 7 129 245

Fordringer

Kundefordringer 7 687 706
Andre fordringer 1 693 843 148 880
Selskapskatt 591 647 65 316
Konsernfordringer 6 591 390
Sum fordringer 9 973 196 6 805 586

Bankinnskudd, kontanter og lignende

Bankinnskudd, kontanter og lignende 1 852 821 2 501 854
Sum bankinnskudd, kontanter og lignende 1 852 821 2 501 854

Sum omløpsmidler 18 955 262 9 307 440

SUM EIENDELER 19 286 019 9 503 420

BALANSE - EGENKAPITAL OG GJELD

Egenkapital

Innskutt egenkapital

Selskapskapital 50 000 50 000
Sum innskutt egenkapital 50 000 50 000

Opptjent egenkapital

Annen egenkapital 7 578 522 6 038 017
Sum opptjent egenkapital 7 578 522 6 038 017

Sum egenkapital 7 628 522 6 088 017

Sum langsiktig gjeld 0 0

Kortsiktig gjeld



Leverandørgjeld	2 042 121	876 879
Kortsiktig konserngjeld	4 137 586	
Annen kortsiktig gjeld	5 477 790	2 538 524
Sum kortsiktig gjeld	11 657 497	3 415 403
Sum gjeld	11 657 497	3 415 403
SUM EGENKAPITAL OG GJELD	19 286 019	9 503 420



Organisasjonsnr: 922 215 871
JAZZ PHARMACEUTICALS DENMARK APS

NOTEOPPLYSNINGER - SELSKAP - alle poster oppgitt i hele tall

Note
0

Regnskapsprinsipper
Se side 9-11 i vedlagte PDF

Note
1

Lønn og ytelser

Note
1

Antall årsverk i regnskapsåret

Virksomheten har hatt følgende antall årsverk:
14.00



Crowe Statsautoriseret
Revisionsinteressentskab v.m.b.a.

Rygårds Allé 104
DK-2900 Hellerup

Telefon +45 39 29 25 00
www.crowe.dk

Jazz Pharmaceuticals Denmark ApS

c/o Regus Management, Lautruphøj 1
2750 Ballerup

CVR no. 39 79 14 47

Annual report for 2020

(2nd Financial year)

Adopted at the annual general meeting
on 31 July 2021

Joseph Dagher
chairman

CVR nr. 33 25 68 76



Table of contents

	Page
Statements	
Statement by management on the annual report	1
Independent auditor's report	2
Management's review	
Company details	5
Management's review	6
Financial statements	
Accounting policies	7
Income Statement	11
Balance Sheet	12
Statement of changes in equity	14
Notes to the annual report	15



Statement by management on the annual report

The executive board has today discussed and approved the annual report of Jazz Pharmaceuticals Denmark ApS for the financial year 1 January - 31 December 2020.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In my opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2020 and of the results of the company's operations for the financial year 1 January - 31 December 2020.

In my opinion, management's review includes a fair review of the matters dealt with in the management's review.

Management recommends that the annual report should be approved by the company in general meeting.

Ballerup, 22 July 2021

Executive board

Samantha Jane Laura Pearce
Director



Independent auditor's report

To the management of Jazz Pharmaceuticals Denmark ApS

Opinion

We have audited the financial statements of Jazz Pharmaceuticals Denmark ApS for the financial year 1 January - 31 December 2020, which comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared under the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2020 and of the results of the company's operations for the financial year 1 January - 31 December 2020 in accordance with the Danish Financial Statements Act.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements, that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



Independent auditor's report

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on management's review

Management is responsible for management's review.

Our opinion on the financial statements does not cover management's review, and we do not express any form of assurance conclusion thereon.



Independent auditor's report

In connection with our audit of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.

Copenhagen, 22 July 2021

KPMG

Statsautoriseret Revisionspartnerselskab

CVR no. 25 57 81 98

Christian Engelbrecht Friis

State Authorized Public Accountant

MNE no. mne44180



Company details

The company

Jazz Pharmaceuticals Denmark ApS
c/o Regus Management, Lautruphøj 1
2750 Ballerup

CVR no.: 39 79 14 47

Reporting period: 1 January - 31 December 2020

Incorporated: 17 August 2018

Domicile: Ballerup

Executive board

Samantha Jane Laura Pearce, director

Auditors

KPMG
Statsautoriseret Revisionspartnerselskab
Dampfærgevej 28
2100 København Ø



Management's review

Business review

The purpose of the company is promotion, distribution and sale of pharmaceutical products and services, including all activity deemed relevant by the management of the company.

Financial review

The company's income statement for the year ended 31 December 2020 shows a profit of DKK 1.540.505, and the balance sheet at 31 December 2020 shows equity of DKK 7.628.522.

Significant events occurring after the end of the financial year

No events have occurred after the balance sheet date which could significantly affect the company's financial position.



Accounting policies

The annual report of Jazz Pharmaceuticals Denmark ApS for 2020 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, as well as provisions applying to reporting class C entities.

The accounting policies applied are consistent with those of last year.

The annual report for 2020 is presented in DKK

Basis of recognition and measurement

Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item.

Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any installments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount.

On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.

Income statement

Gross profit

In pursuance of section 32 of the Danish Financial Statements Act, the company does not disclose its revenue.

Gross profit reflects an aggregation of revenue, changes in inventories of finished goods, costs of raw materials and consumables and other external expenses.

Revenue

Income from the sale of goods for resale is recognised in the income statement, provided that the transfer of risk, usually on delivery to the buyer, has taken place and that the income can be measured reliably and is expected to be received.



Accounting policies

Other external costs

Other external costs include expenses related to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts relating to the financial period. Net financials include interest income and expenses, realised and unrealised exchange gains and losses on foreign currency transactions and surcharges and allowances under the advance-payment-of-tax scheme, etc.

Tax on profit/loss for the period

Tax for the period, which comprises the current tax charge for the period and changes in the deferred tax charge, is recognised in the income statement as regards the portion that relates to the profit/loss for the period and directly in equity as regards the portion that relates to entries directly in equity.

Balance sheet

Stocks

Stocks are measured at cost using the FIFO method. Where the net realisable value is lower than the cost, inventories are recognised at this lower value.

The cost of goods for resale, raw materials and consumables comprises the purchase price plus delivery costs.

Receivables

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable is impaired, an impairment loss for that individual asset is recognised.

Equity

Dividends

Proposed dividends are disclosed as a separate item under equity. Dividends are recognised as a liability when declared by the annual general meeting of shareholders.

Income tax and deferred tax

Current tax liabilities and current tax receivables are recognised in the balance sheet as the estimated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and tax paid on account.

Deferred tax is measured according to the liability method in respect of temporary differences between the carrying amount of assets and liabilities and their tax base, calculated on the basis of the planned use of the asset and settlement of the liability, respectively. Deferred tax is measured at net realisable value.



Accounting policies

Liabilities

Liabilities, which include trade payables, payables to group entities and other payables, are measured at amortised cost, which is usually equivalent to nominal value.



Accounting policies

Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or financial expenses. If foreign currency instruments are considered cash flow hedges, any unrealised value adjustments are taken directly to a fair value reserve under 'Equity'.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses.



Income statement
1 January 2020 - 31 December 2020

	<u>Note</u>	<u>12 months 2020 DKK</u>	<u>17 months 2018/19 DKK</u>
Gross profit		16.469.482	7.280.478
Staff costs	1	<u>-14.301.578</u>	<u>-7.644.373</u>
Profit/loss before net financials		2.167.904	-363.895
Financial costs	2	<u>-333.292</u>	<u>-258.084</u>
Profit/loss before tax		1.834.612	-621.979
Tax on profit/loss for the period	3	<u>-294.107</u>	<u>138.296</u>
Profit/loss for the year		<u>1.540.505</u>	<u>-483.683</u>
Recommended appropriation of profit/loss			
Retained earnings		<u>1.540.505</u>	<u>-483.683</u>
		<u>1.540.505</u>	<u>-483.683</u>



Balance sheet at 31 December 2020

	<u>Note</u>	<u>2020</u> DKK	<u>2019</u> DKK
Assets			
Finished goods and goods for resale		7.129.245	0
Stocks		<u>7.129.245</u>	<u>0</u>
Trade receivables		7.687.706	0
Receivables from group enterprises		0	6.591.390
Other receivables		1.693.843	148.880
Deferred tax asset		330.757	195.980
Corporation tax		591.647	65.316
Receivables		<u>10.303.953</u>	<u>7.001.566</u>
Cash at bank and in hand		<u>1.852.821</u>	<u>2.501.854</u>
Total current assets		<u>19.286.019</u>	<u>9.503.420</u>
Total assets		<u>19.286.019</u>	<u>9.503.420</u>



Balance sheet at 31 December 2020

	<u>Note</u>	<u>2020</u> DKK	<u>2019</u> DKK
Equity and liabilities			
Share capital		50.000	50.000
Retained earnings		<u>7.578.522</u>	<u>6.038.017</u>
Equity		<u>7.628.522</u>	<u>6.088.017</u>
Trade payables		2.042.121	876.879
Payables to group enterprises		4.137.586	0
Other payables		<u>5.477.790</u>	<u>2.538.524</u>
Total current liabilities		<u>11.657.497</u>	<u>3.415.403</u>
Total liabilities		<u>11.657.497</u>	<u>3.415.403</u>
Total equity and liabilities		<u>19.286.019</u>	<u>9.503.420</u>
Contingent liabilities	4		
Mortgages and collateral	5		



Statement of changes in equity

	<u>Share capital</u>	<u>Retained earnings</u>	<u>Total</u>
Equity at 1 January 2020	50.000	6.038.017	6.088.017
Net profit/loss for the year	0	1.540.505	1.540.505
Equity at 31 December 2020	<u>50.000</u>	<u>7.578.522</u>	<u>7.628.522</u>



Notes

	12 months 2020 DKK	17 months 2018/19 DKK
1 Staff costs		
Wages and salaries	12.545.219	6.852.402
Pensions	1.158.881	416.490
Other social security costs	597.478	375.481
	<u>14.301.578</u>	<u>7.644.373</u>
Average number of employees	<u>14</u>	<u>3</u>
2 Financial costs		
Interest paid to group enterprises	231.843	157.603
Other financial costs	101.449	100.481
	<u>333.292</u>	<u>258.084</u>
3 Tax on profit/loss for the period		
Current tax for the period	428.884	57.684
Deferred tax for the period	-134.777	-195.980
	<u>294.107</u>	<u>-138.296</u>
4 Contingent liabilities		
None.		
5 Mortgages and collateral		
None.		